{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T20:47:27Z","timestamp":1791406047324,"version":"4.3.3"},"reference-count":104,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.bcp.2012.12.011","type":"journal-article","created":{"date-parts":[[2012,12,24]],"date-time":"2012-12-24T22:01:19Z","timestamp":1356386479000},"page":"727-744","source":"Crossref","is-referenced-by-count":137,"title":["Antivirals: Past, present and future"],"prefix":"10.1016","volume":"85","author":[{"given":"Erik","family":"De Clercq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2012.12.011_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-3527(09)73001-5","article-title":"Looking back in 2009 at the dawning of antiviral therapy now 50 years ago an historical perspective","volume":"73","author":"De Clercq","year":"2009","journal-title":"Adv Virus Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0010","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0006-3002(59)90597-9","article-title":"Synthesis and biological activities of iododeoxyuridine, an analog of thymidine","volume":"32","author":"Prusoff","year":"1959","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bcp.2012.12.011_bib0015","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3181\/00379727-73-17652","article-title":"Activity of p-aminobenzaldehyde, 3-thiosemicarbazone on vaccinia virus in the chick embryo and in the mouse","volume":"73","author":"Hamre","year":"1950","journal-title":"Proc Soc Exp Biol Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0020","doi-asserted-by":"crossref","first-page":"305","DOI":"10.4049\/jimmunol.67.4.305","article-title":"Studies on the chemotherapy of vaccinia virus. II. The activity of some thiosemicarbazones","volume":"67","author":"Hamre","year":"1951","journal-title":"J Immunol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0025","first-page":"35","article-title":"Thiosemicarbazones","volume":"vol. 1","author":"Bauer","year":"1972"},{"key":"10.1016\/j.bcp.2012.12.011_bib0030","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0140-6736(63)90230-7","article-title":"Prophylactic treatment of smallpox contacts with N-methylisatin-\u03b2-thiosemicarbazone","volume":"ii","author":"Bauer","year":"1963","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2012.12.011_bib0035","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","article-title":"Virus interference. I. The interferon","volume":"147","author":"Isaacs","year":"1957","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"10.1016\/j.bcp.2012.12.011_bib0040","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1126\/science.144.3620.862","article-title":"Antiviral activity of 1-adamantanamine (amantadine)","volume":"144","author":"Davies","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.12.011_bib0045","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barr\u00e9-Sinoussi","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.12.011_bib0050","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.6600519","article-title":"Isolation and transmission of human retrovirus (human t-cell leukemia virus)","volume":"219","author":"Popovic","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.12.011_bib0055","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1126\/science.6091268","article-title":"Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III","volume":"226","author":"Mitsuya","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.12.011_bib0060","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0140-6736(85)91162-6","article-title":"Antimoniotungstate (HPA 23) treatment of three patients with AIDS and one with prodrome","volume":"1","author":"Rozenbaum","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2012.12.011_bib0065","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(85)90002-9","article-title":"Effects of suramin on HTLV-III\/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo","volume":"ii","author":"Broder","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2012.12.011_bib0070","doi-asserted-by":"crossref","first-page":"7096","DOI":"10.1073\/pnas.82.20.7096","article-title":"3\u2032-Azido-3\u2032-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III\/lymphadenopathy-associated virus in vitro","volume":"82","author":"Mitsuya","year":"1985","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2012.12.011_bib0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bcp.2012.12.011_bib0080","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/rmv.624","article-title":"The history of antiretrovirals: key discoveries over the past 25 years","volume":"19","author":"De Clercq","year":"2009","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0085","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.bcp.2012.03.024","article-title":"Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era","volume":"84","author":"De Clercq","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0090","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/med.21267","article-title":"Tenofovir: quo vadis anno 2012 (where is it going in the year 2012)","volume":"32","author":"De Clercq","year":"2012","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2012.12.011_bib0095","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1126\/science.2523562","article-title":"Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome","volume":"244","author":"Choo","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.12.011_bib0100","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1126\/science.2496467","article-title":"An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis","volume":"244","author":"Kuo","year":"1989","journal-title":"Science"},{"issue":"Suppl. 1","key":"10.1016\/j.bcp.2012.12.011_bib0105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1478-3231.2008.01925.x","article-title":"Discovery of the hepatitis C virus","volume":"29","author":"Houghton","year":"2009","journal-title":"Liver Int"},{"key":"10.1016\/j.bcp.2012.12.011_bib0110","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2012.12.011_bib0115","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0120","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0125","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","article-title":"Telaprevir for previously treated chronic HCV infection","volume":"362","author":"McHutchison","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0130","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","article-title":"Telaprevir for previously untreated chronic hepatitis C virus infection","volume":"364","author":"Jacobson","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0135","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1010494","article-title":"Boceprevir for untreated chronic HCV genotype 1 infection","volume":"364","author":"Poordad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0140","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/nature02099","article-title":"An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus","volume":"426","author":"Lamarre","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2012.12.011_bib0145","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/nrd2424","article-title":"The design of drugs for HIV and HCV","volume":"6","author":"De Clercq","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.12.011_bib0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/rmv.1727","article-title":"The race for interferon-free HCV therapies: a snapshot by the spring of 2012","volume":"22","author":"De Clercq","year":"2012","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0155","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1056\/NEJM197609022951001","article-title":"Effect of human leukocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis","volume":"295","author":"Greenberg","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0160","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3181\/00379727-109-27169","article-title":"Clinical cure of herpes simplex keratitis by 5-iodo-2\u2032-deoxyuridine","volume":"109","author":"Kaufman","year":"1962","journal-title":"Proc Soc. Exp Biol Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0165","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1126\/science.145.3632.585","article-title":"Therapeutic antiviral action of 5-trifluoromethyl-2\u2032-deoxyuridine in herpes simplex keratitis","volume":"145","author":"Kaufman","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.bcp.2012.12.011_bib0170","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJM197605272942201","article-title":"Adenine arabinoside therapy of herpes zoster in the immunosuppressed. NIAID collaborative antiviral study","volume":"294","author":"Whitley","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0175","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1056\/NEJM197708112970601","article-title":"Adenine arabinoside therapy of biopsy-proved herpes simplex encephalitiis. National Institute of Allergy and Infectious Diseases collaborative antiviral study","volume":"297","author":"Whitley","year":"1977","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0180","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1056\/NEJM199102143240703","article-title":"A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group","volume":"324","author":"Whitley","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0185","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1073\/pnas.74.12.5716","article-title":"Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl)guanine","volume":"74","author":"Elion","year":"1977","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2012.12.011_bib0190","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/272583a0","article-title":"9-(2-Hydroxyethoxymethyl) guanine activity against viruses of the herpes group","volume":"272","author":"Schaeffer","year":"1978","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2012.12.011_bib0195","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nm0402-386","article-title":"Herpes simplex virus helicase\u2013primase inhibitors are active in animal models of human disease","volume":"8","author":"Crute","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0200","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nm0402-392","article-title":"New helicase\u2013primase inhibitors as drug candidates for the treatment of herpes simplex disease","volume":"8","author":"Kleymann","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0205","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1128\/AAC.46.6.1766-1772.2002","article-title":"Potent in vivo antiviral activity of the herpes simplex virus primase-helicase inhibitor BAY 57-1293","volume":"46","author":"Betz","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0210","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.antiviral.2006.11.006","article-title":"The helicase primase inhibitor, BAY 57-1293 shows potent therapeutic antiviral activity superior to famciclovir in BALB\/c mice infected with herpes simplex virus type 1","volume":"75","author":"Biswas","year":"2007","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0215","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.bcp.2004.07.039","article-title":"Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster","volume":"68","author":"De Clercq","year":"2004","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0220","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/med.10035","article-title":"Highly potent and selective inhibition of varicella-zoster virus replication by bicyclic furo[2,3-d]pyrimidine nucleoside analogues","volume":"23","author":"De Clercq","year":"2003","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2012.12.011_bib0225","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1021\/jm000210m","article-title":"Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain","volume":"43","author":"McGuigan","year":"2000","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2012.12.011_bib0230","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1128\/AAC.49.3.1081-1086.2005","article-title":"Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides","volume":"49","author":"Andrei","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0235","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkm376","article-title":"Preclinical development of bicyclic nucleoside analogues as potent and selective inhibitors of varicella zoster virus","volume":"60","author":"McGuigan","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0240","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3851\/IMP1472","article-title":"FV-100: the most potent and selective anti-varicella zoster virus agent reported to date","volume":"20","author":"Migliore","year":"2010","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0245","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1128\/AAC.01446-10","article-title":"Pharmacokinetics and safety of FV-100, a novel oral anti-herpes zoster nucleoside analogue, administered in single and multiple doses to healthy young adult and elderly adult volunteers","volume":"55","author":"Pentikis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0250","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1517\/14728214.2011.591786","article-title":"Emerging drugs for varicella-zoster virus infections","volume":"16","author":"Andrei","year":"2011","journal-title":"Expert Opin Emerg Drugs"},{"key":"10.1016\/j.bcp.2012.12.011_bib0255","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/jac\/dkg205","article-title":"New inhibitors of human cytomegalovirus (HCMV) on the horizon","volume":"51","author":"De Clercq","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0260","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.virusres.2010.11.004","article-title":"The search for new therapies for human cytomegalovirus infections","volume":"147","author":"Prichard","year":"2011","journal-title":"Virus Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0265","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.coviro.2011.10.015","article-title":"Progress in the development of new therapies for herpesvirus infections","volume":"1","author":"Price","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0270","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.antiviral.2006.05.002","article-title":"Antiviral drugs for cytomegalovirus diseases","volume":"71","author":"Biron","year":"2006","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0275","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3851\/IMP1885","article-title":"Scientific report: highlights of 24th ICAR, 8-11 May 2011, Sofia, Bulgaria","volume":"22","author":"Vere Hodge","year":"2011","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0280","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am J Transpl"},{"key":"10.1016\/j.bcp.2012.12.011_bib0285","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/nrd2175","article-title":"Antiviral agents active against influenza A viruses","volume":"5","author":"De Clercq","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bcp.2012.12.011_bib0290","doi-asserted-by":"crossref","first-page":"e1001079","DOI":"10.1371\/journal.ppat.1001079","article-title":"Characterization of oseltamivir-resistant 2009 H1N1 pandemic influenza A viruses","volume":"6","author":"Kiso","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bcp.2012.12.011_bib0295","doi-asserted-by":"crossref","first-page":"e37095","DOI":"10.1371\/journal.pone.0037095","article-title":"I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275Y","volume":"7","author":"LeGoff","year":"2012","journal-title":"PLoS One"},{"issue":"Sep","key":"10.1016\/j.bcp.2012.12.011_bib0300","doi-asserted-by":"crossref","first-page":"e1002914","DOI":"10.1371\/journal.ppat.1002914","article-title":"H1N1 2009 pandemic influenza virus: resistance of the I223R neuraminidase mutant explained by kinetic and structural analysis","volume":"8","author":"van der Vries","year":"2012","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.bcp.2012.12.011_bib0525","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1093\/infdis\/jis633","article-title":"Molecular mechanisms underlying oseltamivir resistance mediated by an I117V substitution in the neuraminidase of subtype H5N1 avian influenza A viruses","volume":"207","author":"Takano","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0310","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1128\/AAC.00474-10","article-title":"Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection","volume":"54","author":"Kohno","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/cid\/cis351","article-title":"mergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virus","volume":"55","author":"Sorbello","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0320","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1093\/cid\/cis352","article-title":"Peramivir use for treatment of hospitalized patients with influenza A(H1N1)pdm09 under emergency use authorization, October 2009\u2013June 2010","volume":"55","author":"Yu","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0325","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3851\/IMP1688","article-title":"Laninamivir and its prodrug, CS-8958: long-acting neuraminidase inhibitors for the treatment of influenza","volume":"21","author":"Yamashita","year":"2010","journal-title":"Antivir Chem Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0330","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.ijantimicag.2012.06.017","article-title":"Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance","volume":"40","author":"Kashiwagi","year":"2012","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.bcp.2012.12.011_bib0335","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/656802","article-title":"Long-acting neuraminidase inhibitor laninamivir octanoate versus oseltamivir for treatment of influenza: a double-blind, randomized, noninferiority clinical trial","volume":"51","author":"Watanabe","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0340","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1086\/591851","article-title":"Developing new antiviral agents for influenza treatment: what does the future hold","volume":"48","author":"Hayden","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0345","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1093\/infdis\/jis571","article-title":"Presence of oseltamivir-resistant pandemic A\/H1N1 minor variants before drug therapy with subsequent selection and transmission","volume":"206","author":"Ghedin","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0350","doi-asserted-by":"crossref","first-page":"10558","DOI":"10.1128\/JVI.00985-12","article-title":"Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation","volume":"86","author":"Wong","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0355","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/jac\/dks337","article-title":"Five years of non-prescription oseltamivir: effects on resistance, immunization and stockpiling","volume":"67","author":"Gauld","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0360","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/med.20173","article-title":"Yet another ten stories on antiviral drug discovery (part D): paradigms, paradoxes, and paraductions","volume":"30","author":"De Clercq","year":"2010","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2012.12.011_bib0365","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.antiviral.2012.03.001","article-title":"Combinations of favipiravir and peramivir for the treatment of pandemic influenza A\/California\/04\/2009 (H1N1) virus infections in mice","volume":"94","author":"Tarbet","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0370","doi-asserted-by":"crossref","first-page":"e29778","DOI":"10.1371\/journal.pone.0029778","article-title":"Triple combination antiviral drug (TCAD) composed of amantadine, oseltamivir, and ribavirin impedes the selection of drug-resistant influenza A virus","volume":"6","author":"Hoopes","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.bcp.2012.12.011_bib0375","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1128\/CMR.14.2.382-397.2001","article-title":"Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections","volume":"14","author":"De Clercq","year":"2001","journal-title":"Clin Microb Rev"},{"key":"10.1016\/j.bcp.2012.12.011_bib0380","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3201\/eid0701.010125","article-title":"Strengthening national preparedness for smallpox: an update","volume":"7","author":"LeDuc","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0385","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3201\/eid0807.020032","article-title":"Smallpox research activities: U.S. interagency collaboration, 2001","volume":"8","author":"LeDuc","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0390","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.antiviral.2012.02.012","article-title":"Orthopoxvirus targets for the development of new antiviral agents","volume":"94","author":"Prichard","year":"2012","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0395","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/med.20153","article-title":"Another ten stories in antiviral drug discovery (part C): old and new antivirals, strategies, and perspectives","volume":"29","author":"De Clercq","year":"2009","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2012.12.011_bib0400","doi-asserted-by":"crossref","unstructured":"De Clercq E. Highlights in antiviral drug research: antivirals at the horizon. Med Res Rev 2013, in press.","DOI":"10.1002\/med.21256"},{"key":"10.1016\/j.bcp.2012.12.011_bib0405","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0166-3542(87)80004-9","article-title":"Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines","volume":"8","author":"De Clercq","year":"1987","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0410","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/nrmicro975","article-title":"Antivirals and antiviral strategies","volume":"2","author":"De Clercq","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0415","first-page":"181","article-title":"Tecovirimat, a p37 envelope protein inhibitor for the treatment of smallpox infection","volume":"13","author":"Duraffour","year":"2010","journal-title":"IDrugs"},{"key":"10.1016\/j.bcp.2012.12.011_bib0420","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.3390\/v2112409","article-title":"Development of ST-246\u00ae for treatment of poxvirus infections","volume":"2","author":"Jordan","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2012.12.011_bib0425","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.3390\/v2122681","article-title":"Treatment of vaccinia and cowpox virus infections in mice with CMX001 and ST-246","volume":"2","author":"Quenelle","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.bcp.2012.12.011_bib0430","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1128\/AAC.00762-07","article-title":"Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses","volume":"51","author":"Quenelle","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0435","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/infdis\/jis510","article-title":"Progressive vaccinia: case description and laboratory-guided therapy with vaccinia immune globulin, ST-246, and CMX001","volume":"206","author":"Lederman","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0440","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/nature04295","article-title":"Antiviral treatment is more effective than smallpox vaccination upon lethal monkeypox virus infection","volume":"439","author":"Stittelaar","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2012.12.011_bib0445","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1093\/infdis\/jir853","article-title":"Detection of molluscum contagiosum virus (MCV) DNA in the plasma of an immunocompromised patient and possible reduction of MCV DNA with CMX-001","volume":"205","author":"Cohen","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0450","doi-asserted-by":"crossref","first-page":"4728","DOI":"10.1128\/AAC.00545-11","article-title":"CMX001 potentiates the efficacy of acyclovir in herpes simplex virus infections","volume":"55","author":"Prichard","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0455","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00705-008-0088-8","article-title":"Nobel Prizes and the emerging virus concept","volume":"153","author":"Norrby","year":"2008","journal-title":"Arch Virol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0460","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. Effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bcp.2012.12.011_bib0465","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1128\/AAC.33.8.1291","article-title":"Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and their 5\u2032-nor derivatives","volume":"33","author":"De Clercq","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bcp.2012.12.011_bib0470","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1021\/jm00127a007","article-title":"Synthesis of 3-deazaneplanocin A, a powerful inhibitor of S-adenosylhomocysteine hydrolase with potent and selective in vitro and in vivo antiviral activities","volume":"32","author":"Tseng","year":"1989","journal-title":"J Med Chem"},{"key":"10.1016\/j.bcp.2012.12.011_bib0475","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0166-3542(00)00066-8","article-title":"Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-l-homocysteine hydrolase inhibitor","volume":"45","author":"Bray","year":"2000","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0480","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0166-3542(02)00018-9","article-title":"3-Deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice","volume":"55","author":"Bray","year":"2002","journal-title":"Antiviral Res"},{"key":"10.1016\/j.bcp.2012.12.011_bib0485","doi-asserted-by":"crossref","first-page":"17339","DOI":"10.1073\/pnas.1010026107","article-title":"Rigid amphipathic fusion inhibitors, small molecule antiviral compounds against enveloped viruses","volume":"107","author":"St Vincent","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2012.12.011_bib0490","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1073\/pnas.0909587107","article-title":"A broad-spectrum antiviral targeting entry of enveloped viruses","volume":"107","author":"Wolf","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bcp.2012.12.011_bib0495","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1086\/525049","article-title":"A large vaccine-derived poliovirus outbreak on Madura Island \u2013 Indonesia, 2005","volume":"197","author":"Est\u00edvariz","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0500","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1002\/med.20149","article-title":"Antiviral drug discovery: ten more compounds, and ten more stories (part B)","volume":"29","author":"De Clercq","year":"2009","journal-title":"Med Rev Rev"},{"key":"10.1016\/j.bcp.2012.12.011_bib0505","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1086\/525050","article-title":"The demise and rebirth of polio \u2013 a modern phoenix","volume":"197","author":"Wright","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.bcp.2012.12.011_bib0510","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1002\/med.20125","article-title":"Selective inhibitors of picornavirus replication","volume":"28","author":"De Palma","year":"2008","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bcp.2012.12.011_bib0515","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1128\/JVI.01338-07","article-title":"The thiazolobenzimidazole TBZE-029 inhibits enterovirus replication by targeting a short region immediately downstream from motif C in the nonstructural protein 2C","volume":"82","author":"De Palma","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.bcp.2012.12.011_bib0520","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3201\/eid1404.070439","article-title":"Potential use of antiviral agents in polio eradication","volume":"14","author":"De Palma","year":"2008","journal-title":"Emerg Infect Dis"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295212007976?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295212007976?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,4]],"date-time":"2024-05-04T00:10:30Z","timestamp":1714781430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295212007976"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":104,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0006295212007976"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2012.12.011","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}